CL2015003635A1 - Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos útiles como inhibidores de quinasa. - Google Patents
Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos útiles como inhibidores de quinasa.Info
- Publication number
- CL2015003635A1 CL2015003635A1 CL2015003635A CL2015003635A CL2015003635A1 CL 2015003635 A1 CL2015003635 A1 CL 2015003635A1 CL 2015003635 A CL2015003635 A CL 2015003635A CL 2015003635 A CL2015003635 A CL 2015003635A CL 2015003635 A1 CL2015003635 A1 CL 2015003635A1
- Authority
- CL
- Chile
- Prior art keywords
- tetrahydrocarbazole
- kinase inhibitors
- compounds useful
- carboxamide compounds
- substituted carboxamide
- Prior art date
Links
- XKLNOVWDVMWTOB-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1h-carbazole Chemical group N1C2=CC=CC=C2C2=C1CCCC2 XKLNOVWDVMWTOB-UHFFFAOYSA-N 0.000 title abstract 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N Carbazole Chemical group C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 title 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 title 1
- -1 carboxamide compounds Chemical class 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- GZSUIHUAFPHZSU-UHFFFAOYSA-N 9-ethyl-2,3-dihydro-1h-carbazol-4-one Chemical compound C12=CC=CC=C2N(CC)C2=C1C(=O)CCC2 GZSUIHUAFPHZSU-UHFFFAOYSA-N 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361839141P | 2013-06-25 | 2013-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015003635A1 true CL2015003635A1 (es) | 2016-07-29 |
Family
ID=51210830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015003635A CL2015003635A1 (es) | 2013-06-25 | 2015-12-15 | Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos útiles como inhibidores de quinasa. |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US9334290B2 (https=) |
| EP (1) | EP3013814B1 (https=) |
| JP (1) | JP6353529B2 (https=) |
| KR (1) | KR102346508B1 (https=) |
| CN (1) | CN105358546B (https=) |
| AR (1) | AR096721A1 (https=) |
| AU (1) | AU2014302548B2 (https=) |
| BR (1) | BR112015030723A8 (https=) |
| CA (1) | CA2916500A1 (https=) |
| CL (1) | CL2015003635A1 (https=) |
| CY (1) | CY1119371T1 (https=) |
| DK (1) | DK3013814T3 (https=) |
| EA (1) | EA026729B1 (https=) |
| ES (1) | ES2636652T3 (https=) |
| HR (1) | HRP20171031T1 (https=) |
| HU (1) | HUE034460T2 (https=) |
| IL (1) | IL243296B (https=) |
| LT (1) | LT3013814T (https=) |
| MA (1) | MA38648B1 (https=) |
| MY (1) | MY176631A (https=) |
| PE (1) | PE20160519A1 (https=) |
| PH (1) | PH12015502630A1 (https=) |
| PL (1) | PL3013814T3 (https=) |
| PT (1) | PT3013814T (https=) |
| RS (1) | RS56371B1 (https=) |
| SI (1) | SI3013814T1 (https=) |
| SM (1) | SMT201700422T1 (https=) |
| TN (1) | TN2015000529A1 (https=) |
| TW (1) | TWI648272B (https=) |
| UY (1) | UY35625A (https=) |
| WO (1) | WO2014210085A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014302550A1 (en) | 2013-06-25 | 2016-02-11 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
| MX2017005060A (es) | 2014-10-24 | 2017-07-05 | Bristol Myers Squibb Co | Compuestos atropisomeros triciclicos. |
| PE20190710A1 (es) | 2014-10-24 | 2019-05-17 | Bristol Myers Squibb Co | Compuestos de indol carboxamida utiles como inhibidores de cinasas |
| RS59707B1 (sr) * | 2014-10-24 | 2020-01-31 | Bristol Myers Squibb Co | Derivati karbazola |
| MX2018015793A (es) | 2016-07-01 | 2019-03-21 | Brio Device Llc | Estilete de intubación con alimentación de video. |
| CN108101905A (zh) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 |
| CA3045339A1 (en) | 2016-12-03 | 2018-06-07 | Juno Therapeutics, Inc. | Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors |
| WO2018118830A1 (en) | 2016-12-20 | 2018-06-28 | Bristol-Myers Squibb Company | Process for preparing tetrahydrocarbazole carboxamide compound |
| WO2019208805A1 (ja) | 2018-04-27 | 2019-10-31 | 小野薬品工業株式会社 | Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤 |
| CN117285467A (zh) | 2018-07-31 | 2023-12-26 | 罗索肿瘤学公司 | 喷雾干燥的分散体和制剂 |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| EP4313023A1 (en) | 2021-04-02 | 2024-02-07 | Biogen MA Inc. | Combination treatment methods of multiple sclerosis |
| AR128498A1 (es) * | 2022-02-15 | 2024-05-15 | Hoffmann La Roche | Procesos novedosos |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
| CA2140722A1 (en) | 1994-01-24 | 1995-07-25 | Joseph A. Jakubowski | Beta-carboline thromboxane synthase inhibitors |
| US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| WO2005005429A1 (en) | 2003-06-30 | 2005-01-20 | Cellular Genomics, Inc. | Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds |
| WO2005047290A2 (en) | 2003-11-11 | 2005-05-26 | Cellular Genomics Inc. | Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors |
| EP1812439B2 (en) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| AU2005304473A1 (en) | 2004-11-10 | 2006-05-18 | Cgi Pharmaceuticals, Inc. | Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
| BRPI0517211B8 (pt) | 2004-12-17 | 2021-05-25 | Glenmark Pharmaceuticals Sa | composto, composição farmacêutica e seu uso. |
| MX2007011041A (es) | 2005-03-10 | 2008-02-22 | Cgi Pharmaceuticals Inc | Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas. |
| US20070185184A1 (en) * | 2005-09-16 | 2007-08-09 | Serenex, Inc. | Carbazole derivatives |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| JP5249772B2 (ja) | 2005-11-22 | 2013-07-31 | メルク・シャープ・アンド・ドーム・コーポレーション | キナーゼの阻害剤として有用な三環式化合物 |
| WO2008033858A2 (en) | 2006-09-11 | 2008-03-20 | Cgi Pharmaceuticals, Inc. | Kinase inhibitors, and methods of using and identifying kinase inhibitors |
| CA2663178C (en) | 2006-09-11 | 2016-01-12 | Matrix Laboratories Ltd. | Dibenzofuran derivatives as inhibitors of pde-4 and pde-10 |
| US20090062251A1 (en) | 2007-08-17 | 2009-03-05 | Astrazeneca Ab | Novel Compounds 002 |
| AU2008335761B2 (en) | 2007-12-13 | 2014-04-24 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| EP2247558B2 (en) | 2008-02-14 | 2024-07-03 | Eli Lilly and Company | Novel imaging agents for detecting neurological dysfunction |
| GB0809360D0 (en) | 2008-05-22 | 2008-07-02 | Isis Innovation | Calcium modulation |
| EP2151441A1 (en) | 2008-08-06 | 2010-02-10 | Julius-Maximilians-Universität Würzburg | Beta-carbolin-derivates as substrates for an enzyme |
| US8084620B2 (en) * | 2008-12-19 | 2011-12-27 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
| CN101475571B (zh) | 2009-01-21 | 2011-06-22 | 中国药科大学 | β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途 |
| US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
| AU2011232058B2 (en) | 2010-03-26 | 2016-09-08 | Merck Patent Gmbh | Benzonaphthyridinamines as autotaxin inhibitors |
| WO2011159857A1 (en) * | 2010-06-16 | 2011-12-22 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
| EP2455378A1 (en) | 2010-11-03 | 2012-05-23 | Philip Morris Products S.A. | Carbazole and carboline derivatives, and preparation and therapeutic applications thereof |
| EP2640729B1 (en) | 2010-11-15 | 2016-12-21 | VIIV Healthcare UK Limited | Inhibitors of hiv replication |
| AU2012257802A1 (en) | 2011-05-17 | 2013-10-31 | F. Hoffmann-La Roche Ag | Inhibitors of Bruton's tyrosine kinase |
| WO2013054185A1 (en) | 2011-10-13 | 2013-04-18 | Pfizer, Inc. | Pyrimidine and pyridine derivatives useful in therapy |
-
2014
- 2014-06-24 TW TW103121681A patent/TWI648272B/zh not_active IP Right Cessation
- 2014-06-24 AR ARP140102388A patent/AR096721A1/es unknown
- 2014-06-24 UY UY0001035625A patent/UY35625A/es unknown
- 2014-06-25 HR HRP20171031TT patent/HRP20171031T1/hr unknown
- 2014-06-25 SI SI201430268T patent/SI3013814T1/sl unknown
- 2014-06-25 MA MA38648A patent/MA38648B1/fr unknown
- 2014-06-25 CN CN201480035611.8A patent/CN105358546B/zh not_active Expired - Fee Related
- 2014-06-25 RS RS20170904A patent/RS56371B1/sr unknown
- 2014-06-25 PL PL14740094T patent/PL3013814T3/pl unknown
- 2014-06-25 EP EP14740094.9A patent/EP3013814B1/en active Active
- 2014-06-25 EA EA201592287A patent/EA026729B1/ru not_active IP Right Cessation
- 2014-06-25 US US14/314,602 patent/US9334290B2/en active Active
- 2014-06-25 KR KR1020167001632A patent/KR102346508B1/ko not_active Expired - Fee Related
- 2014-06-25 CA CA2916500A patent/CA2916500A1/en not_active Abandoned
- 2014-06-25 ES ES14740094.9T patent/ES2636652T3/es active Active
- 2014-06-25 TN TN2015000529A patent/TN2015000529A1/en unknown
- 2014-06-25 PE PE2015002665A patent/PE20160519A1/es active IP Right Grant
- 2014-06-25 LT LTEP14740094.9T patent/LT3013814T/lt unknown
- 2014-06-25 DK DK14740094.9T patent/DK3013814T3/en active
- 2014-06-25 PT PT147400949T patent/PT3013814T/pt unknown
- 2014-06-25 JP JP2016523869A patent/JP6353529B2/ja not_active Expired - Fee Related
- 2014-06-25 WO PCT/US2014/043978 patent/WO2014210085A1/en not_active Ceased
- 2014-06-25 BR BR112015030723A patent/BR112015030723A8/pt not_active Application Discontinuation
- 2014-06-25 HU HUE14740094A patent/HUE034460T2/en unknown
- 2014-06-25 SM SM20170422T patent/SMT201700422T1/it unknown
- 2014-06-25 AU AU2014302548A patent/AU2014302548B2/en not_active Ceased
- 2014-06-25 MY MYPI2015704738A patent/MY176631A/en unknown
-
2015
- 2015-11-26 PH PH12015502630A patent/PH12015502630A1/en unknown
- 2015-12-15 CL CL2015003635A patent/CL2015003635A1/es unknown
- 2015-12-22 IL IL243296A patent/IL243296B/en active IP Right Grant
-
2016
- 2016-03-11 US US15/067,915 patent/US20160194338A1/en not_active Abandoned
-
2017
- 2017-06-16 US US15/625,417 patent/US9850258B2/en active Active
- 2017-09-06 CY CY20171100943T patent/CY1119371T1/el unknown
- 2017-11-10 US US15/809,437 patent/US10106559B2/en active Active
-
2018
- 2018-09-25 US US16/140,750 patent/US10435415B2/en active Active
-
2019
- 2019-08-22 US US16/547,675 patent/US20190382416A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015003635A1 (es) | Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos útiles como inhibidores de quinasa. | |
| CL2016000925A1 (es) | Inhibidores de bromodominio | |
| CL2016003398A1 (es) | Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo. | |
| CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CL2015003280A1 (es) | Derivados de benzimidazol como inhibidores de bromodominio | |
| ECSP17016797A (es) | Indazoles sustituidos con benzilo como inhibidores de bub1 | |
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| MX2016002137A (es) | Ciertas entidades quimicas, composiciones y metodos. | |
| CL2016002877A1 (es) | Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos. | |
| CL2016001737A1 (es) | Derivados heterocíclicos bicíclicos como inhibidores de bromodominio | |
| UY35500A (es) | Indazoles sustituidos con heteroarilo | |
| DK3539961T3 (da) | Polycykliske amidderivativer som cdk9-inhibitorer | |
| CL2016001101A1 (es) | Compuestos de piridilo sustituidos con alquilamida útiles como moduladores de respuestas de il-12 e il-23 y/o ifnalfa | |
| EA201891209A1 (ru) | Модуляторы хемокиновых рецепторов | |
| CL2015002658A1 (es) | Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio | |
| CL2015003314A1 (es) | Inhibidores de acc y usos de los mismos | |
| CL2016001911A1 (es) | Compuesto heterocíclico fusionado | |
| CU20160162A7 (es) | Derivados de pirrolidina-2,5-diona,para usar como inhibidores ido1 y composiciones farmacéuticas que los contienen | |
| MX2020012165A (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer. | |
| CL2016001973A1 (es) | Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza. | |
| CL2018000696A1 (es) | Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue. | |
| CL2015002855A1 (es) | Derivados de oxopiridina sustituida. | |
| CL2013002898A1 (es) | Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer. | |
| CL2015002932A1 (es) | Inhibidores de proteína quinasa | |
| CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . |